Value through Innovation27 July 2016

Clinical Study Results

  • MOBIC ® - Respiratory Tract Infections
    Clinical Study Number 107.250
    Study Indication Respiratory Tract Infections
    Product MOBIC ®
    Generic Name Meloxicam
    Lab Code
    Clinical Phase IV
    Study Title

    Randomized, open-label, controlled trial to assess the clinical efficacy and safety of meloxicam suspension 0.25 mg/kg/day once a day, versus diclofenac 1 mg/kg/day twice a day or nimesulide 4 mg/kg/day twice a day, for five days in the treatment of patients with acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis

    Study Document Trial synopsis 107.250 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.